2018
Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy
Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M. Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology 2018, 67: 972-988. PMID: 28836688, PMCID: PMC5783790, DOI: 10.1002/hep.29400.Peer-Reviewed Original ResearchMeSH KeywordsAminophenolsAminopyridinesAnimalsBenzodioxolesBiliary TractCell Culture TechniquesChloride Channel AgonistsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorCytokinesCytoskeletonEpithelial CellsFluorescent Antibody TechniqueHumansInduced Pluripotent Stem CellsInflammationMiceMicroscopy, ConfocalPyrimidinesQuinolonesSignal TransductionSrc-Family KinasesConceptsBiliary epitheliumCystic fibrosisToll-like receptor 4Cystic fibrosis transmembrane conductance regulatorFluid secretionActivated B cells (NF-κB) activationClinical liver diseaseStrong translational potentialCause of deathB cell activationSrc kinase inhibitionFibrosis transmembrane conductance regulatorTransmembrane conductance regulatorInflammatory changesPharmacological therapyProinflammatory changesProinflammatory chemokinesInflammation contributesLiver diseaseHuman cholangiopathiesReceptor 4Healthy controlsLiver patientsCF patientsVX-770
1984
Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
Okolicsanyi L, Venuti M, Strazzabosco M, Orlando R, Nassuato G, Iemmolo R, Lirussi F, Muraca M, Pastorino A, Castelli G. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis. International Journal Of Clinical Pharmacology And Therapeutics 1984, 22: 329-32. PMID: 6086536.Peer-Reviewed Original ResearchConceptsCompensated liver cirrhosisLiver cirrhosisPharmacokinetics of ranitidineCirrhotic patientsUrinary recoveryUnchanged drugHealthy controlsPlasma concentrationsIntravenous pharmacokineticsPharmacokinetic dataPatientsCirrhosisOral bioavailabilityRanitidinePharmacokineticsHigh-performance liquid chromatographyPerformance liquid chromatographyCirrhoticsLiquid chromatographyControl